
July 13, 2023 Expert interview on the use of AI in the ATMP industry
Contract Development and Manufacturing Organizations (CDMOs) are realizing that digital transformation is now crucial for business, that is, developing and delivering treatments quickly to patients in need. In the ATMP industry, “automation technologies and Artificial Intelligence (AI) are recognized as an absolute requirement”, Yatindra states. “They reduce user errors,” he says. “Furthermore, automation and AI allow for the integration of disruptive technologies while maintaining compliance. This highlights the connection between compliance and the never-ending process of innovation. They both complement one another.”
If you would like to learn more about the current digital trends and their positive impact on the cell and gene therapy industry, you can find the full interview here.
Contact Person:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Senior Director Corporate Communication
communications@rentschler-biopharma.com